An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK)

Name: An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK)
Published: 2023
License: Public Domain

AbbVie · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

crohn-s-disease

crohn's disease, risankizumab, skyrizi, observational

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK)

Related documents